Aarti Pharmalabs Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Aarti Pharmalabs Ltd is ₹ 708.1 as of 18 May 16:01 . The P/E Ratio of Aarti Pharmalabs Ltd changed from 12.9 on March 2023 to 24.9 on March 2025 . This represents a CAGR of 24.51% over 3 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Aarti Pharmalabs Ltd changed from ₹ 2489 crore on March 2023 to ₹ 6784 crore on March 2025 . This represents a CAGR of 39.69% over 3 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 436.83 crore as compare to the Sep '25 revenue of ₹ 418.39 crore. This represent the growth of 4.41% The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The ebitda of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 104.07 crore as compare to the Sep '25 ebitda of ₹ 74.13 crore. This represent the growth of 40.39% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The net profit of Aarti Pharmalabs Ltd changed from ₹ 55.45 crore to ₹ 47.96 crore over 7 quarters. This represents a CAGR of -7.96% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 17.61 % on March 2025 . This represents a CAGR of 18.62% over 3 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Aarti Pharmalabs Ltd

Aarti Pharmalabs Limited was initially incorporated as 'Aarti Organics Limited' in 2019.
The name of the Company was changed to Aarti Pharmachem Limited from Aarti Organics Limited' in July, 2021 and to Aarti Pharmalabs Limited in 2022.
Company is a manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Aarti Pharmalabs Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Aarti Pharmalabs Ltd or Shilpa Medicare Ltd?

Market cap of Aarti Pharmalabs Ltd is 6,480 Cr while Market cap of Shilpa Medicare Ltd is 9,358 Cr

What are the key factors driving the stock performance of Aarti Pharmalabs Ltd and Shilpa Medicare Ltd?

The stock performance of Aarti Pharmalabs Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Pharmalabs Ltd and Shilpa Medicare Ltd?

As of May 18, 2026, the Aarti Pharmalabs Ltd stock price is INR ₹714.8. On the other hand, Shilpa Medicare Ltd stock price is INR ₹478.5.

How do dividend payouts of Aarti Pharmalabs Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Aarti Pharmalabs Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.